Abstract
BACKGROUND
Short stature represents one of the main features of children with Noonan syndrome. The reason for impaired growth remains largely unknown.
OBJECTIVE
To assess GH and IGF1 secretion in children with Noonan syndrome. Patients: 12 prepubertal children with Noonan syndrome due to mutations in the PTPN11 gene [7 males, 6 females; median age, years: 8.6 (range 5.1–13.4)] were studied; 12 prepubertal children with short stature (SS) [7 males, 5 females; median age, years: 8.1 (range 4.8–13.1)] served as the control group. Measurements: GH secretion after arginine stimulation test; IGF1 generation test by measurement of IGF1 levels before and after recombinant GH (rGH) administration (0.05 mg/kg/day for 4 days).
RESULTS
Baseline and stimulated peak values of GH were not significantly different between the two groups. At +120 minutes, GH levels remained significantly higher (p = 0.0121) in comparison with baseline values in children with Noonan syndrome. Baseline IGFI levels in patients and in SS controls were not significantly different, in contrast to values after the rGH generation test [205 ng/mL (interquartiles 138.2–252.5 ng/mL) and 284.5 ng/mL (inter-quartiles 172–476 ng/mL), respectively; p = 0.0248]. IGF1 values were significantly related to height (baseline: r = 773, p = 0.0320; peak: r = 0.591, p = 0.0428) in children with Noonan syndrome.
CONCLUSIONS
Blunted increase of IGF1 after the rGH generation test was present in children with Noonan syndrome due to mutations in the PTPN11 gene in comparison with SS children. This finding may be due to partial GH resistance in the former likely related to altered Ras-MAPK signaling pathway.
Similar content being viewed by others
References
Padidela R, Camacho-Hübner C, Attie KM, Savage MO, 2008 Abnormal growth in Noonan syndrome: genetic and endocrine features and optimal treatment. Horm Res 70: 129–136.
van der Burgt I, 2007 Noonan syndrome. Orphanet J Rare Dis 2: 4.
Tartaglia M, Gelb BD, 2005 Noonan syndrome and related disorders: genetics and pathogenesis. Ann Rev Genom Hum Genet 6, 45–68.
Sarkozy A, Digilio MC, Marino B, Mingarelli R, Tartaglia M, Dalla Piccola B, 2006 Noonan’s syndrome and related disorders: clinical molecular update and guidelines. Ital J Pediatr 32: 45–155.
Neel BG, Gu H, Pao L, 2003 The ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sciences 28: 284–293.
Shaw AC, Kalidas K, Crosby AH, Jeffery S, Patton MA, 2007 The natural history of Noonan syndrome: a long-term follow-up study. Arch Dis Child 92: 128–132.
Ranke MB, Heidemann P, Knupfer C, Enders H, Schmaltz AA, Bierich JR, 1988. Noonan syndrome: growth and clinical manifestations in 144 cases. Eur J Pediatr 148: 220–227.
Noonan JA, Raaijmakers R, Hall BD, 2003 Adult height in Noonan syndrome. Am J Med Genet A 123A: 68–71.
Smpokou P, Tworog-Dube E, Kucherlapati RS, Roberts AE, 2012 Medical complications, clinical findings, and educational outcomes in adults with Noonan syndrome. Am J Med Genet A 158A: 3106–3111.
Cotterill AM, McKenna WJ, Brady AF, et al, 1996 The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan’s syndrome. J Clin Endocrinol Metab 81: 2291–2297.
Romano AA, Blethen SL, Dana K, Noto RA, 1996 Growth hormone treatment in Noonan syndrome: the National Cooperative Growth Study experience. Pediatrics 128: S18–21.
Tanaka K, Sato A, Naito T, Kuramochi K, Itabashi H, Takemura Y, 1992 Noonan syndrome presenting growth hormone neurosecretory dysfunction. Int Med 31: 908–911.
Binder G, Neuer K, Ranke MB, Wittekindt NE, 2005 PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 90: 5377–5381.
Limal JM, Parfait B, Cabrol S, et al, 2006 Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab 91: 300–306.
Ferreira LV, Souza SA, Arnhold IJ, Mendonca BB, Jorge AA 2005 PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome. J Clin Endocrinol Metab 90: 5156–5160.
Noordam C, van der Burgt I, Sweep CG, Delemarrevan de Waal HA, Sengers RC, Otten BJ, 2001 Growth hormone (GH) secretion in children with Noonan syndrome: frequently abnormal without consequences for growth or response to GH treatment. Clinical Endocrinol (Oxf) 54: 53–59.
Blum F, Cotterill AM, Postel-Vinay MC, Ranke MB, Savage MO, Wilton P, 1994 Improvement of diagnostic criteria in growth hormone insensitivity syndrome: solutions and pitfalls. Pharmacia study group on insulin-like growth factor I treatment in growth hormone insensitivity syndromes. Acta Paediatrica Suppl 399: 117–124.
Pessoa de Queiroz AN, Collett-Solberg PF, Cardoso ME, Jusan RC, Vaisman M, Gurmarães MM, 2007 IGF-I, IGFBP-3 and ALS generation test in Turner syndrome. Growth Hormone & IGF Research 17: 254–260.
Selva KA, Buckway CK, Sexton G, et al, 2003 Reproducibility in patterns of IGF generation with special reference to idiopathic short stature. Horm Res 60: 237–246.
Cacciari E, Milani S, Balsamo A, et al, 2006 Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocr Invest 29: 581–593.
Greulich WW, Pyle SI, 1959 Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford, CA: Stanford University Press.
Carrillo AA, Bao Y, 2007 Hormonal dynamic tests and genetic tests used in pediatric endocrinology. In “Pediatric Endrocrinology”, 5th ed, ch 33, pp 737–767. ed Lifshitz F. New York, NY: Informa Healthcare USA, Inc.
Cappa M, Loche S, 2005 Clinical and laboratory evaluation of short statured children. Ital J Pediatr 31: 26–32.
De Lima Jorge AA, 2007 Diagnosis and long-term human growth hormone treatment of a boy with Noonan syndrome. Horm Res 67: Suppl 1: 98–101.
Juul A, Bang P, Hertel NT, et al, 1994 Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78: 744–752.
Jorge AA, Souza SC, Arnhold IJ, Mendonca BB, 2002 Poor reproducibility of IGF-I and IGF binding protein-3 generation test in children with short stature and normal coding region of the GH receptor gene. J Clin Endocrinol Metab 87: 469–472.
Rosenfeld RG, Belgorosky A, Camacho-Hubner C, Savage MO, Wit JM, Hwa V, 2007 Defects in growth hormone receptor signaling. Trends Endocrinol Metab 18: 134–141.
Capalbo D, Melis D, De Martino L, et al, 2012 Noonan-like syndrome with loose anagen hair associated with growth hormone insensitivity and atypical neurological manifestations. Am J Med Genet A 158A: 856–860.
Cordeddu V, Di Schiavi E, Pennacchio LA, et al, 2009 Mutation of SHOC2 promotes aberrant protein Nmyristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet 41: 1022–1026.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bertelloni, S., Baroncelli, G.I., Dati, E. et al. IGF-I generation test in prepubertal children with Noonan syndrome due to mutations in the PTPN11 gene. Hormones 12, 86–92 (2013). https://doi.org/10.1007/BF03401289
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03401289